GlassScriptPhysician profile
Gardner Fletcher
NPI 1114982485
$6,051.99
in general payments reported to CMS, 2019-2025
23 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $737 · 2021: $867 · 2022: $1,068 · 2023: $952 · 2024: $818 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,016 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,015.66 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,555.40 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $988.40 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $826.71 | 2020-2025 | Breztri, Symbicort, Airsupra |
| Grifols USA, LLC | $630.07 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $482.70 | 2019-2024 | Yupelri |
| Insmed, INC. | $341.87 | 2020-2024 | Arikayce |
| Viatris Specialty LLC | $182.15 | 2025 | Yupelri |
| Verona Pharma, INC. | $152.78 | 2025 | Ohtuvayre |
| Genzyme Corporation | $111.43 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $100.31 | 2019-2023 | Opsumit |
| Pfizer INC. | $93.94 | 2021-2023 | |
| Electromed, INC. | $90.00 | 2023-2024 | Smartvest |
| Mallinckrodt Hospital Products INC. | $81.57 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $58.54 | 2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $52.26 | 2022-2025 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $52.14 | 2020 | |
| Genentech USA, INC. | $48.14 | 2019 | |
| Philips North America LLC | $47.71 | 2023-2025 | Vest Therapy Und |
| Vifor Pharma, INC. | $43.21 | 2024-2025 | Zemaira |
| Amarin Pharma, INC. | $31.91 | 2019-2020 | |
| Gilead Sciences, INC. | $31.33 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $24.90 | 2019 | |
| Stryker Corporation | $24.52 | 2025 | Flowtriever |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gardner Fletcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.